Efficacy of Acupuncture as a Treatment for Faecal Incontinence

March 17, 2020 updated by: Singapore General Hospital

Overall Aim:

To improve the long-term management outcomes for faecal incontinence (FI); through the implementation of new alternative treatment to complement existing treatment options, and enable better utilization of limited healthcare resources.

Primary Specific Aim:

To evaluate the effectiveness of Traditional Chinese Medicine (TCM) acupuncture in the treatment of faecal incontinence.

Secondary Aims:

  • To evaluate the safety profile of TCM acupuncture.
  • To explore the patient satisfaction and uptake of TCM acupuncture as an alternative management strategy for FI.
  • To evaluate improvements in health-related quality of life with TCM-acupuncture.
  • To explore the cost-effectiveness of TCM acupuncture.

Hypothesis:

Traditional Chinese Medicine therapy, in the form of acupuncture, is an effective treatment for faecal incontinence.

Study Overview

Status

Unknown

Conditions

Detailed Description

Experimental design and procedure The study will run as a prospective, multi-centre, randomised controlled trial of patients with faecal incontinence of best medical therapy versus TCM-Acupuncture.

Patient reported outcome measures and assessments will be carried out to assess primary and secondary outcomes at the commencement of trial, after 10 weeks of the intervention, then again at 15 weeks.

Recruitment procedure Patients will be recruited from Singapore General Hospitals' Colorectal Surgery Department. SGH possess a fully staffed pelvic floor unit specialising in the treatment of faecal incontinence. Eligible patients will be assessed and counselled by a member of the colorectal surgical team. They will then attend for consenting and baseline assessment.

The clinicians will inform the patient during the initial consultation about the different treatments available for their condition as well as this study. As is normal clinical practice, the clinicians will explain the risks and benefits of all the treatment options. Each potential participant will be provided with a patient information sheet. Those who consent to inclusion will then be contacted by a member of the research team. Informed consent will be taken in the clinic environment.

Randomisation Patients will be randomised into one of two groups, to receive acupuncture treatment (INTERVENTION GROUP) or to have best medical therapy (BMT) (CONTROL GROUP). Both patients in the INTERVENTION GROUP and CONTROL GROUP will continue their previous medication, if any, throughout the duration of the study. This is to standardise the 'steady-state' existing in this often elderly population, already subject to polypharmacy.

Patients in the INTERVENTION GROUP will undergo acupuncture therapy at the Singapore College of Traditional Chinese Medicine (SC-TCM), performed by a team of TCM practitioners regularly using acupuncture in the treatment of faecal incontinence and bowel conditions. This regimen will comprise 3 sessions per week each lasting 1 hour, over a period of 10 weeks, for a total of 30 sessions.

Patients in the CONTROL GROUP will undergo BMT as defined previously for the same period of 10 weeks.

Patients will be asked to maintain a simple bowel diary, and answer the FIQL and St Marks' incontinence scores at weeks 0, 10, and 15 to record the primary and secondary outcome measurements. Anorectal Physiology will be offered to patients at 0 and 10 weeks, but for the purposes of this study protocol, will be purely voluntary. We understand that this invasive examination would be a significant undertaking and potential barrier to recruitment for many patients.

Follow up procedure Patient follow-up will consist of three visits to the hospital following the randomisation to either arm of the study. This will be at the 5 week period, 10 week period and 15 week period of the study, where the primary and secondary outcomes measurements will be assessed.

Randomisation and allocation Participants will be randomised to one of the two study groups in equal proportion using a blinded bag shuffling method. This will take place upon agreement to participate.

Measures of outcome Primary outcome: Bowel diary - Incontinence episodes per week Secondary outcomes: St Marks' incontinence score, Faecal Incontinence Quality of Life (FIQL) score, Anorectal manometry scores (at week 0, and 10 weeks) - optional for participants. Analysis plans and sample size sought The primary end-point of the study was defined as the difference in weekly faecal incontinence episodes when comparing patients randomized to the INTERVENTION and CONTROL arms. The secondary endpoint of the study was defined as the difference in St Marks' score and FIQL when comparing patients randomized to the INTERVENTION and CONTROL arms.

Sample Size To detect a difference of 30% between the two arms, assuming that the proportion of incontinence episodes in the conservative arm is 20%, a total sample size of 90 will be required at alpha=0.05 with 80% power. Accounting for a drop-out rate of 10%, the total sample size required is 100, to be recruited over 30 months.

Statistical analysis Continuous data will be summarized as mean (SD) or median (IQR) as appropriate and categorical/binary data as frequency (%). Statistical significance will be set at 0.05. Intention to treat (ITT) analysis will be performed.

The primary hypothesis will be evaluated using a Chi-square test or a Fisher's exact test as appropriate. Additionally, we will also model the outcome using a generalized linear model with a logit link. The possible treatment effect modification of clinically important factors (age, gender, ASA status) will be evaluated in the model.

The secondary hypothesis to evaluate the St Marks' score will be assessed using a two-sample t-test assuming that the score can be treated as a continuous measure. The difference in the FIQL between the two arms will also be tested using the two-sample t-test.

Study Type

Interventional

Enrollment (Anticipated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients presenting with faecal incontinence
  • At least 2 episodes of faecal incontinence per week, St Mark's incontinence score of 5 or greater
  • Patients aged 21 years or older
  • Prior colonoscopy done to exclude underlying colonic pathology
  • Written informed consent obtained

Exclusion Criteria:

  • Active inflammation of the bowel, including inflammatory bowel disease, infection or perianal sepsis
  • Pregnant women
  • Current or previous diagnosis of the gastrointestinal tract, genitourinary, or pelvic cancers
  • Presence of congenital or acquired neurological deficits (including spinal disorders)
  • Previous history of complex major pelvic, anal or rectal surgery
  • Previous history of multi-focal or major sphincter injuries or deficits

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Acupuncture

Acupuncture Regime:

2-3 sessions per week, each lasting an hour, over a period of 10 weeks (with deviation of 2 weeks for scheduling), total of 30 sessions

Acupuncture sessions - 2-3 times/week, each session lasting 1 hour, over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling)
Active Comparator: Best medical therapy

Best Medical Therapy Regime:

3 sessions to be completed over a period of 10 weeks (with deviation of 2 weeks for scheduling), with subjects learning and practicing biofeedback exercises daily

Best Medical Therapy - 3 biofeedback sessions over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling), where subjects learn and practice the exercises daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients who showed improvement in weekly number of incontinence episodes (baseline compare to subjects' week 10)
Time Frame: 10 weeks
Assessed for superiority of intervention arm compared to the control arm
10 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean change in St Mark's incontinence score
Time Frame: 10 weeks
Mean change in St Mark's incontinence score at week 10 from baseline (superiority comparison)
10 weeks
Mean change in Faecal Incontinence Quality of Life (FIQL) score
Time Frame: 10 weeks
Mean change in Faecal Incontinence Quality of Life (FIQL) score at week 10 from baseline (superiority comparison)
10 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean change in anorectal manometry scores
Time Frame: 10 weeks
Mean change in anorectal manometry scores at week 10 from baseline (superiority comparison)
10 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Emile Kwong Wei Tan, Singapore General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 7, 2018

Primary Completion (Anticipated)

November 30, 2020

Study Completion (Anticipated)

November 30, 2020

Study Registration Dates

First Submitted

February 18, 2020

First Submitted That Met QC Criteria

February 18, 2020

First Posted (Actual)

February 19, 2020

Study Record Updates

Last Update Posted (Actual)

March 19, 2020

Last Update Submitted That Met QC Criteria

March 17, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Faecal Incontinence

Clinical Trials on Acupuncture

3
Subscribe